Michaël Hocquemiller, PhD
Michaël Hocquemiller is scientific director at Lysogene. He has 10 years of experience in research and drug development in the biotechnology industry, focused on neurodegenerative diseases. Dr. Hocquemiller has co-led the Phase 1 clinical trial in MPS IIIA, as well as designing drug candidates and pre-clinical work that have now advanced into clinical development. Before joining Lysogene, Dr. Hocquemiller worked as a research scientist at the Pasteur Institute focused on Sanfilippo syndrome neurophysiopathology and gene therapy correction in animal models. Dr. Hocquemiller has a PhD in neuroscience from the University Paris Descartes (Paris V) and a Masters in genetics from the University Pierre and Marie Curie (Paris VI).